Nearly 93% of the U.S. population lives in a hospital referral region with at least one medical center that performs 25 or more mitral valve repairs or replacements each year, according to work published in JAMA Cardiology—but MVRR centers continue to suffer from significant geographical and patient-level disparities.

An economic analysis of COAPT data suggests edge-to-edge TMVR with the MitraClip device is a more affordable long-term treatment option than guideline-directed medical therapy alone for patients with severe secondary MR—but the steep cost of an index TMVR procedure might eclipse that benefit.

Results from the COAPT study continue to roll in, and it was all positive news for the MitraClip team at the TCT conference in San Francisco this month.

A recent analysis of the COAPT trial, published this spring in the Journal of the American College of Cardiology, suggests patients with symptomatic heart failure (HF) and secondary mitral regurgitation (MR) might see better mental and physical outcomes if they’re treated with edge-to-edge transcatheter mitral valve repair (TMVR) in lieu of standard therapy.

The Pascal transcatheter mitral valve repair (TMVR) system has received its CE mark for the treatment of patients with mitral regurgitation, device manufacturer Edwards Lifesciences announced Feb. 19.

The use of transcatheter mitral valve repair (TMVR) systems continues to grow rapidly nearly six years after the FDA approved the U.S.'s first such treatment, according to research published in the American Journal of Cardiology. In contrast, rates of surgical mitral valve repair (SMVR) have remained steady.

Abbott plans to acquire Cephea Valve Technologies, a company developing a transcatheter mitral valve replacement (TMVR) device, the Chicago-area healthcare giant announced Jan. 16.

Will operators be able to replicate COAPT’s restraint and its outcomes?